Compare drug alternatives
Cinryze® Alternatives
Cinryze®(C1 esterase inhibitor (human)) | Firazyr®(icatibant) |
---|---|
Prescription Only | Prescription Only |
Dosage & Administration | |
Administration | |
Intravenous. Learn more. | Subcutaneous. Learn more. |
Dosing | |
Adults and Children >12: 1,000 IU Intravenous every 3 or 4 days. Children 6-11: 500 IU Intravenous every 3 or 4 days.. Learn more. | 30 mg injected subcutaneously in the abdominal area. If response is inadequate or symptoms recur, additional injections of 30 mg may be administered at intervals of at least 6 hours. Do not administer more than 3 injections in 24 hours.. Learn more. |
Latin Shorthand | |
Adults and Children >12: 1,000 IU IV q3-4d. Children 6-11: 500 IU IV q3-4d.. Learn more. | Administer 30 mg SC in the abdominal area. If insufficient response or symptom recurrence, give additional 30 mg injections at intervals of at least 6 hours. Do not exceed 3 injections within 24 hours.. Learn more. |
Financial Assistance | |
Out-Of-Pocket Costs With Copay Card | |
$0. Learn more. | $0. Learn more. |
Annual Cap | |
$40,000. Learn more. | |
Assistance Expiration | |
Generics | |
No lower-cost generic available | No lower-cost generic available |
Physician Advisory | |
Adverse Reactions | |
The most common adverse reactions (≥5%) observed were headache,
nausea, rash, vomiting, and fever.. Learn more. | The most commonly reported adverse reactions were injection site
reactions, which occurred in almost all patients (97%) in clinical trials.
Other common adverse reactions occurring in greater than 1% of patients
included pyrexia, transaminase increase, dizziness, and rash.. Learn more. |
Mechanism of Actions (MoA) | |
Drugs used in Hereditary Angioedema. Learn more. | Drugs used in Hereditary Angioedema. Learn more. |
Special Populations | |
1. Is CINRYZE safe to use during pregnancy? There are no specific data available regarding the use of CINRYZE in pregnant women. Animal studies have not been conducted to assess its effects on pregnancy. Whether CINRYZE can cause harm to a developing fetus or affect reproductive capacity in pregnant women is unknown. It should only be administered to a pregnant woman if it is clearly needed. 2. What is the background risk of birth defects and miscarriage in the general U.S. population? In the U.S. general population, the estimated background risk of major birth defects in clinically recognized pregnancies is 2 to 4%, and the risk of miscarriage is estimated to be 15 to 20%. 3. Is there any information on the use of CINRYZE during lactation? There is no available data regarding the presence of CINRYZE in human milk, its effects on breastfed infants, or its impact on milk production. When considering the use of CINRYZE, the benefits of breastfeeding, both for the infant's development and the mother's clinical need, should be weighed against any potential adverse effects on the breastfed child. 4. Has CINRYZE been tested in pediatric patients? Yes, the safety and effectiveness of CINRYZE have been evaluated in pediatric subjects with hereditary angioedema (HAE) aged 7 to 11 years old. Additionally, some subjects under the age of 18 were included in trials, and overall, the safety and tolerability of CINRYZE were found to be similar in pediatric, adolescent, and adult subjects. The pharmacokinetics of CINRYZE were also assessed in pediatric subjects aged 7 to 11 years old. 5. Is CINRYZE suitable for use in geriatric patients? Clinical studies of CINRYZE did not include a sufficient number of subjects aged 65 and over to determine if they respond differently from younger subjects. Reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for an elderly patient should be cautious, typically starting at the lower end of the dosing range, considering the higher likelihood of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies. | 1. Is it safe to use FIRAZYR during pregnancy? Available data from published literature and the pharmacovigilance database have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes with FIRAZYR use in pregnant women. Animal studies showed some effects on fetal development in rabbits at high doses, but no such effects were observed in rats. The estimated background risk of major birth defects and miscarriage in the general population is 2% to 4% and 15% to 20%, respectively. 2. What do we know about FIRAZYR use during lactation? There is no data on the presence of icatibant (FIRAZYR) in human milk, its effects on the breastfed infant, or its impact on milk production. Icatibant was found in rat milk following subcutaneous administration, suggesting it might be present in human milk. However, systemic absorption of icatibant in infants is not expected after oral exposure through breast milk. When considering the use of FIRAZYR, the potential benefits of breastfeeding for the infant's development and health should be weighed against the mother's clinical need for FIRAZYR and any potential adverse effects on the breastfed child from FIRAZYR or the maternal condition. 3. Is FIRAZYR safe for use in pediatric patients? Safety and effectiveness of FIRAZYR have not been established in pediatric patients below the age of 18 years. There is evidence of potential juvenile toxicity in young male rats, including delayed sexual maturation and impaired fertility, but no such effects were observed in females. 4. Is FIRAZYR suitable for use in geriatric patients? Clinical studies of FIRAZYR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Elderly patients are likely to have increased systemic exposure to FIRAZYR, but no dose adjustment is recommended as there have been no identified differences in efficacy and safety between elderly and younger patients. 5. How does hepatic impairment affect FIRAZYR use? FIRAZYR was studied in patients with mild to moderate hepatic impairment, and no change in systemic exposure was noted. Therefore, no dose adjustment is required in patients with hepatic impairment. 6. How does renal impairment affect FIRAZYR use? While a formal renal impairment study has not been conducted, FIRAZYR is cleared non-renally and is not expected to show any change in systemic exposure in patients with impaired renal function. No dose adjustment is required in patients with renal impairment. |
Popular Alternatives
- Cinryze® vs Orladeyo®
- Cinryze® vs Berinert®
- Cinryze® vs Haegarda®
- Cinryze® vs Kalbitor®
- Cinryze® vs Sajazir®
- Cinryze® vs Takhzyro®
- Cinryze® vs Ruconest®